Search Results - matthew+sporn

3 Results

Sort By:

T Cell Receptors Targeting EGFR L858R mutation on HLA-A*11:01+ Tumors for Use as Research Tools

Summary: The Surgery Branch seeks licensees for research use of TCRs targeting EGFR L858R mutation. Description of Technology: Tumor-specific mutated proteins can create neoepitopes, mutation-derived antigens that distinguish tumor cells from healthy cells, which are attractive targets for adoptive cell therapies. However, the process of precisely...

Published: 4/24/2026 | Updated: 2/16/2024 | Inventor(s): Catherine Ade, Matthew Sporn, Zhiya Yu

Keywords(s):

Category(s): Application > Research Materials, Application > Diagnostics, Collaboration Sought > Licensing, TherapeuticArea > Oncology

T Cell Receptors Targeting the KRAS G13D Mutation in the Context of HLA-A11:01 for Research Use

Summary: The National Cancer Institute (NCI) has identified HLA-A11:01-restricted T Cell Receptors (TCRs) targeting the KRAS G13D mutation. The NCI seeks licensees for the use of these TCRs in research. Description of Technology: Tumor-specific mutated proteins can create immunogenic, mutation-containing “neoepitopes” which are attractive...

Published: 4/16/2026 | Updated: 1/16/2024 | Inventor(s): Catherine Ade, Zhiya Yu, Matthew Sporn, James Yang, Kenichi Hanada

Keywords(s):

Category(s): TherapeuticArea, Application, Application > Research Materials, Collaboration Sought > Licensing

T Cell Receptors Targeting BRAF V600E Mutation for Cancer Immunotherapy

Summary: The NCI seeks parties interested in research co-development and/or licensing of these HLA-A*0301 restricted TCRs that target the BRAF V600E mutation. Description of Technology: BRAF is an oncogene that encodinges a serine-threonine kinase (B-Raf kinase) important in regulating cell growth and differentiation. Spontaneous mutations in the...

Published: 4/23/2026 | Updated: 8/2/2023 | Inventor(s): Zhiya Yu, Catherine Ade, Matthew Sporn, James Yang, Kenichi Hanada

Keywords(s): BRAF, B-Raf kinase, B-Raf Proto-Oncogene, HLA-A*0301 restriction, Immunotherapy, Rosenberg, serine-threonine kinase, T Cell Receptor, T cell therapy, TCR, V600E mutation, Yang, Yu

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Collaboration Sought > Licensing